Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Spot on Pilgrim 1 , add me to the list. Will be adding more of these to my SIPP and ISA on any drops over the next few years.
Pilgrim1, ill be here with you!
You're absolutely spot on with your sentiment although I think your figures are a bit light. We know labskin has an 80% profit margin and Rhinocloud services even more so I think you can confirm £3m GP on £4m T/O is still conservative. I think the main difference will be the T/O will be much greater. The £4m estimate is based on only a 30% success rate of potential orders in the pipeline and this pipeline will continue to grow rapidly month on month. Gerard isn't the sort to set false expectations. Also, maybe for such a dynamic expanding company, a PE ratio of 25 is more appropriate. My guestimate is a T/O of approx £7M with a Net profit of £4M - £5M. Even with a PE of 20, then you're looking at c£80M....7/8p....this is all imo and if it doesn't happen next year, then it will in 2021. The company is going global...I'll be here until £30M plus turnover when we get taken out...I don't think I'm the only one either..I've been in shares that have have taken 4 years to go to the dogs...this will not happen here...buy and hold is all you need to do. GLA
has Turner Pope ever provided a price forecast for SKIN? I'm not aware of one.
I think part of the issue is that it's difficult to value a small, fast growing company with limited current revenues - currently c£1m p.a vs £18m current valuation.
The £4m for 2020 provides more clarity - say £2m gross profit and £1m profit net then at a PE of 20 then that's £20m for SKIN.
Ok, not much more than current price BUT £4m appears quite conservative, growth % is fantastic and if Rhinocloud margins are as high as has been quoted maybe the £2m gross profit is nearer £3m.
I can see 3p (so c£30m) in 2020 definitely
Summary:
As Integumen approaches 2020, the company is engaging with a wide range of global
skin and personal care companies and expects that average sales contracts will range
between £100,000 and £500,000 for data as a service and multi-year skincare R&D
framework agreements. Consequently, the company has good revenue visibility and
excluding the likelihood of income that may be generated from the company’s
agreement with Parity, Integumen is providing guidance that revenue will be
approximately £4m in 2020. With the company outlining in early October 2019 that
2019 revenue would exceed the £1m mark, we believe that it is evident that
Integumen’s AI focused strategy is gaining significant momentum.
Link
https://t.co/G4oSuGWJhZ?amp=1